Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

ClinicalTrials.gov ID: NCT01873404

Public ClinicalTrials.gov record NCT01873404. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy

Study identification

NCT ID
NCT01873404
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Biogen
Industry
Enrollment
183 participants

Conditions and interventions

Interventions

  • BG00010 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2013
Primary completion
Feb 28, 2015
Completion
Feb 28, 2015
Last update posted
Sep 9, 2015

2013 – 2015

United States locations

U.S. sites
25
U.S. states
13
U.S. cities
25
Facility City State ZIP Site status
Research Site Phoenix Arizona 85018
Research Site Fresno California 93710
Research Site Lomita California 90717
Research Site Long Beach California 90806
Research Site Pasadena California 91105
Research Site Fort Lauderdale Florida 33312
Research Site Orlando Florida 32806
Research Site Sarasota Florida 34232
Research Site St. Petersburg Florida 33713
Research Site Sunrise Florida 33351
Research Site Tampa Florida 33606
Research Site Winter Park Florida 32789
Research Site Columbus Georgia 31904
Research Site Savannah Georgia 31406
Research Site Bloomington Illinois 61701
Research Site Chicago Illinois 60657
Research Site Evansville Indiana 47714
Research Site Overland Park Kansas 66210
Research Site Brockton Massachusetts 02301
Research Site Lincoln Nebraska 68521
Research Site Raleigh North Carolina 27612
Research Site Winston-Salem North Carolina 27103
Research Site Duncansville Pennsylvania 16635
Research Site San Antonio Texas 78731
Research Site Salt Lake City Utah 84106

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01873404, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2015 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01873404 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →